OLFML2A is necessary for anti-triple negative breast cancer effect of selective activator protein‐1 inhibitor T-5224

• DOI: 10.1016/j.tranon.2021.101100
• Publication Date: 2021-05-13T16:46:07Z
• Authors: Qian Zhao; Kaixin Zhang; Yong Li; Yaxuan Ren; Jikang Shi; Yulu Gu; Shuang Qiu; Sainan Liu; Yi Cheng; Yichun Qiao; Yawen Liu
• Keywords: Triple-negative breast cancer

Previous studies have shown that expression of activator protein-1 (AP-1) family is significantly elevated in triple-negative breast cancer (TNBC), compared with other subtypes. Here we investigated the anti-tumor effect and mechanism T-5224, an inhibitor c-Fos/AP-1, on TNBC. We identified T-5224 inhibited proliferation, migration, invasion TNBC cells resulted increase apoptosis. Furthermore, found OLFML2A a key regulatory protein acting downstream AP-1 involved T-5224-targeted action. Multiple clinical databases online high level associated poor prognosis patients. In summary, our experimental bioinformatic indicated necessary for AP-1-overexpressing These findings demonstrate dependent OLFML2A, targeting both through T‐5224 may be synergistic therapeutic strategy this clinically challenging subset cancer.